Improving Access to Medicines in Low-Income Countries: A Review of Mechanisms

Journal of World Intellectual Property

Volumn 18, Issue 1-2, 2015, Pages 1-28

  Bors, Cindy ^a   Christie, Andrew ^b   Gervais, Daniel ^c   Wright Clayton, Ellen ^d  

^a Kliger Partners   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c VANDERBILT UNIVERSITY LAW SCHOOL   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Africa; Caribbean; TRIPS; WHO

Indexed keywords

EID: 84925597586     PISSN: 14222213     EISSN: 17471796     Source Type: Journal    
DOI: 10.1111/jwip.12032     Document Type: Article

References (141)

1. Abbott . ( 2013) Global Citizenship Report. Available at http://prod2.dam.abbott.com/global/documents/pdfs/abbott-citizenship/globalreports/Abbott_longform_report.pdf [Accessed on November 10, 2014].
2. Almog D.M ( 2005) ' Drug Industry in "Depression"'. Medical Science Monitor, 11(1), SR 1-4.
3. Amin T. and Kesslheim A. ( 2012) ' Secondary Patenting of Branded Pharmaceuticals: A Case Study of How Patents on Two HIV Drugs Could be Extended for Decades', Health Affairs, 31(10), 2286-94.
4. Anley, P. ( 2013) quoted in L. Daniels, New Draft South African IP Policy Receives Initial Positive Reactions [online]. Intellectual Property Watch. Available at http://www.ip-watch.org/2013/09/09/new-south-african-ip-policy-receives-initial-positive-reactions/?utm_source=post&utm_medium=email&utm_campaign=alerts [Accessed on November 10, 2014].
5. Arie, S. ( 2012) ' Contaminated Drugs are Held Responsible for 120 Deaths in Pakistan', British Medical Journal [online], 344:e951. Available at http://dx.doi.org/10.1136/bmj.e951 [Accessed on November 10, 2014].
6. Attaran, A., Barry, D., Shamnad, B., Bate, R., Benton, D., Chauvin, J., Garrett, L., Kickbusch, I., Kohler, J., Midha, K., Newton, P., Nishtar, S., Orhii, P. and McKee, M. ( 2012) ' How to Achieve International Action on Falsified and Substandard Medicines', British Medical Journal [online], 345:e7381. Available at http://www.bmj.com/content/345/bmj.e7381.pdf%2Bhtml [Accessed on November 10, 2014].
7. Baker, B., et al. ( 2013) Open Letter from Global Academics in Support of Proposal to Amend Brazil's Patent Law to Take Advantage of TRIPS-Compliant Flexibilities [online]. Infojustice. Available at http://infojustice.org/support-brazil [Accessed on November 10, 2014].
8. Balasubramaniam, T. ( 2012) Wellcome Trust Tells WHO it Opposes R&D Treaty and the De-Linkage of R&D Costs from Drug Prices [online]. Knowledge Ecology International. Available at http://keionline.org/node/1608 [Accessed October 28, 2014].
9. Bayer . ( 2014) Bayer is committed to fight the Chagas disease [online]. Bayer. Available at http://www.bayer.com/en/chagas-disease.aspx [Accessed on November 4, 2014].
10. Boldrin M. and Levine D. K. ( 2013) ' The Case Against Patents', Journal of Economic Perspectives, 27(1), 3-22.
11. Brennan H., Distler R., Hinman M. and Rogers A. ( 2013) 'A Human Rights Approach to Intellectual Property and Access to Medicines'. Yale Law School and Yale School of Public Health, Global Health Justice Partnership, Policy Paper No. 1. Available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2323144 [Accessed on November 10, 2014].
12. Brenneman A. and Kerf M. ( 2002) Infrastructure and Poverty Linkages: A Literature Review. Available at http://www.ilo.org/wcmsp5/groups/public/-ed_emp/-emp_policy/-invest/documents/publication/wcms_asist_8281.pdf [Accessed on November 10, 2014].
13. Buckley G.J. and Gostin L.O. (eds.) ( 2013) Countering the Problem of Falsified and Substandard Drugs. The National Academies Press, Washington, DC.
14. Burci G. L. ( 2009) ' Public/Private Partnerships in the Public Health Sector', International Organizations Law Review, 6, 359-82.
15. Cameron A., Ewen M., Ross-Degnan D., Ball D. and Laing R. ( 2009) ' Medicine Prices Availability and Affordability in 36 Developing Middle-Income Countries: A Secondary Analysis', The Lancet, 373, 240-49.
16. Carothers C., Heimburger D., Schlachter S., Gardner P., Primack A., Warner T. and Vermund S. ( 2013) ' Training Programs Within Global Networks: Lessons Learned in the Fogarty International Clinical Research Scholars and Fellows Program', The American Journal of Tropical Medicine and Hygiene, 90(1), 173-79.
17. Carpenter J. ( 2004) A Review of Drug Quality in Asia with Focus on Anti-Infectives [online]. US Pharmacopeia. Available at http://pdf.usaid.gov/pdf_docs/PNADH154.pdf [Accessed on November 10, 2014].
18. Centers for Disease Control and Prevention . ( 2011) Ten Great Public Health Achievements - Worldwide (2001-10) [online]. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6024a4.htm [Accessed on November 10, 2014].
19. Cernuschi T., Furrer E., Schwalbe N., Jones A., Berndt E. and McAdams S. ( 2011) Advance Market Commitment for Pneumococcal Vaccines. Bulletin World Health Organization 89, 913. Available at http://www.who.int/bulletin/volumes/89/12/11-087700/en/ [Accessed November 4, 2014].
20. China Food and Drug Administration . Database of Approved Active Pharmaceutical Ingredients and API Manufacturers in China (CFDA). Available at http://app1.sfda.gov.cn/datasearcheng/face3/base.jsp?tableId=85&tableName=TABLE85&title=Database%20of%20approved%20Active%20Pharmaceutical%20Ingredients%20(APIs)%20and%20API%20manufacturers%20in%20China&bcId=136489131226659132460942000667 [Accessed on November 10, 2014].
21. Christie A., Dent C., McIntyre P., Wilson L. and Studdert D. ( 2013) 'Patents Associated with High-Cost Drugs in Australia', PLoS One [online], 8(4), 1-7. Available at http://dx.doi.org/10.1371/journal.pone.0060812 [Accessed on November 10, 2014].
22. Commission on Intellectual Property Rights . ( 2002) Integrating Intellectual Property Rights and Development Policy. Commission on Intellectual Property Rights. Available at http://www.iprcommission.org/papers/pdfs/final_report/ciprfullfinal.pdf [Accessed on October 27, 2014].
23. Commission on Intellectual Property Rights, Innovation and Public Health. ( 2006) Public Health, Innovation and Intellectual Property Rights. World Health Organization, Geneva. Available at http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf?ua=1 [Accessed on October 27, 2014].
24. Committee on Economic, Social and Cultural Rights. ( 2000) General Comment No 14, The Right to the Highest Attainable Standard of Health (Article 12 of the Covenant) [online]. Available at http://tbinternet.ohchr.org/_layouts/treatybodyexternal/Download.aspx?symbolno=E%2fC.12%2f2000%2f4&Lang=en [Accessed on November 10, 2014].
25. Convention on the Elimination of All Forms of Discrimination against, 1 March 1980, United Nations Treaty Series, vol 1249.
26. Convention on the Rights of the Child, 20 November 1989, United Nations Treaty Series, vol. 1577.
27. Czarnitzki D. and Toole A. ( 2011) ' Patent Protection Market Uncertainty, and R&D Investment', The Review of Economics and Statistics, 93(1), 147-59.
28. Daniels L. ( 2013) Comments Received to South Africa's Process for New IP Policy [online]. Intellectual Property Watch. Available at http://www.ip-watch.org/2013/11/18/comments-received-to-south-africas-process-for-new-ip-policy/ [Accessed on November 10, 2014].
29. Department of Essential Drugs and Other Medicines ( 1999) Counterfeit Drugs: Guidelines for the Development of Measures to Combat Counterfeit Drugs. Geneva: World Health Organization.
30. Department of Trade and Industry. ( 2013) Draft National Policy on Intellectual Property (IP) of South Africa: A Policy Framework. Available at http://www.ip-watch.org/weblog/wp-content/uploads/2013/09/SA-IP-Policy-Sept-2013-36816_gen918.pdf [Accessed on November 10, 2014].
31. Farlow A. W. K. ( 2005) ' Accelerating the Innovation of Vaccines: Can the Global HIV Vaccine Enterprise, Malaria Vaccine Initiatives, and Purchase Commitments Deliver?', Innovation Strategy Today, 1(2), 154-65.
32. Farlow A. W. K., Light D.W., Mahoney R. and Widdus R. ( 2005) ' Concerns Regarding the Centre for Global Development Report "Making Markets for Vaccines"', Submission to Commission on Intellectual Property Rights, Innovation and Public Health. Available at http://www.andrewfarlow.com/cipih1may2005.pdf [Accessed on November 4, 2014].
33. Feek C., McKean W., Henneveld L., Barrow G., Edgar W. and Paterson R. ( 1999) ' Experience with Rationing Health Care in New Zealand', British Medical Journal, 318(7194), 1346-48.
34. Flynn S. ( 2008) Appeal of Thailand Commission Order on Abbott's Refusal to Sell AIDS Medications in Thailand [online]. Available at http://www.wcl.american.edu/pijip/thai_comp_licenses.cfm [Accessed on November 10, 2014].
35. Flynn S., Hollis A. and Palmedo M. ( 2009) ' An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries', Journal of Law, Medicine & Ethics: Pharmaceutical Regulations, 37(2), 2-25.
36. Food and Drug Administration. ( 2013) Counterfeit Medicine online]. Food and Drug Administration. Available at http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/CounterfeitMedicine/default.htm [Accessed on November 10, 2014].
37. GAVI Alliance. (2013) Pneumococcal AMC [online]. GAVI Alliance. Available at http://www.gavi.org/funding/pneumococcal-amc/ Accessed on October 28, 2014].
38. General Assembly resolution 217A(III), A/810 (10 December 1948), Health and Disability Services Act 1993, s5 (NZ).
39. Gervais D. ( 2013) 'TRIPS & Development', SAGE Handbook on Intellectual Property. In: David M, and Halbert D (eds). SAGE, London, UK.
40. Gervais D. ( 2014) 'Patentability Criteria as TRIPS Flexibilities: The Examples of China and India', In: Bagley M and Okediji R (eds), Patent Law in a Global Perspective. Oxford University Press, Oxford, UK, pp. 541-569.
41. Global Alliance for TB Drug Development. ( 2014) Operating Model [online]. TB Alliance. Available at http://tballiance.org/about/operating-model.php [Accessed on November 10, 2014].
42. Gold E. R. ( 2013) ' Patents and Human Rights: A Heterodox Analysis', The Journal of Law, Medicine and Ethic, 41(1), 185-98.
43. Gold E. R., Kaplan W., Orbinski J., Harland-Logan S. and N-Marandi S. ( 2010) ' Are Patents Impeding Medical Care and Innovation?', PLoS Medicine, 7(1), e1000208. Available at http://dx.doi.org/10.1371/journal.pmed.1000208 Accessed on November 4, 2014].
44. Gostin L., Buckley G. and Kelley P. ( 2013) ' Stemming the Global Trade in Falsified and Substandard Medicines', Journal of the American Medical Association, 309, 1693-94.
45. Hurlburt S., Mann C., Byam P., Linnander E., Bradley E. and Berman P. ( 2012) Developing Primary Health Care Delivery in Lower and Middle Income Countries: Challenges Faced and Lessons Learned. Report on the Expert Policy Consultation, July 30-31.
46. Ilg M. ( 2010) ' Market Competition in Aid of Humanitarian Concern: Reconsidering Pharmaceutical Drug Patents', Chicago-Kent Journal of Intellectual Property, 9, 149-78.
47. International Covenant on Economic, Social and Cultural Rights, 19 December 1966, United Nations Treaty Series, vol. 993.
48. International Convention on the Elimination of All Forms of Racial Discrimination, 7 March 1966, United Nations Treaty Series, vol. 660.
49. International Covenant on Economic, Social and Cultural Rights, 19 December 1966, United Nations Treaty Series, vol. 993.
50. IMPACT. About Us [online]. World Health Organisation. Available at http://www.who.int/impact/about/en/ [Accessed on November 10, 2014].
51. Infojustice . ( 2013) Brief Technical Overview of Brazil's CNY Proposed Patent Law Reforms. [online]. Infojustice. Available at http://infojustice.org/wp-content/uploads/2013/10/Brief-Technical-Review-of-Brazilian-Leglislation.pdf [Accessed on November 10, 2014].
52. InnoCentive. (2008) Challenge Solution: TB Alliance Works to Eradicate One of the World's Deadliest Diseases [online]. InnoCentive. Available at https://www.innocentive.com/challenge-solution-tb-alliance-works-eradicate-one-world%E2%80%99s-deadliest-diseases [Accessed October 28, 2014].
53. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). ( 2011) Data Exclusivity: Encouraging Development of New Medicines [online]. IFPMA. Available at http://www.ifpma.org/fileadmin/content/Publication/IFPMA_2011_Data_Exclusivity__En_Web.pdf [Accessed on November 4, 2014].
54. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). ( 2012a) The Changing Landscape on Access to Medicines. Available at http://www.ifpma.org/fileadmin/content/Publication/2012/ChangingLandscapes-Web.pdf [Accessed on November 10, 2014].
55. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). ( 2012b) The Pharmaceutical Industry and Global Health: Facts and Figures 2012 [online]. IFPMA. Available at http://www.ifpma.org/fileadmin/content/Publication/2013/IFPMA_-_Facts_And_Figures_2012_LowResSinglePage.pdf [Accessed on November 4, 2014].
56. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). ( 2012c) 'The Threat of False Friends: Joining Efforts to Protect Patients Against Online Sales of Fake Medicines'. Available at http://www.ifpma.org/fileadmin/content/Publication/2012/FIP-IFPMA_brochure._The_threat_of_false_friends._Joining_efforts_to_protect_patients_against_online_sales_of_fake_medicines.pdf [Accessed on November 10, 2014].
57. International Network for Economic, Social & Cultural Rights. ( 2012) Human Rights Enforcement Mechanisms of the United Nations [online]. Available at http://www.escr-net.org/docs/i/405650 [Accessed on November 10, 2014].
58. Interpol. Pharmaceutical Crime [online]. Interpol. Available at http://www.interpol.int/Crime-areas/Pharmaceutical-crime/Pharmaceutical-crime [Accessed on November 10, 2014].
59. Interpol. ( 2013) International Operation Targets Online Sale of Illicit Medicines [online]. Interpol. Available at http://www.interpol.int/News-and-media/News-media-releases/2013/PR077 [Accessed on November 10, 2014].
60. IRIN. ( 2013) The Controversy Over 'Counterfeit' Drugs [online]. IRIN News. Available at http://www.irinnews.org/report/98866/the-controversy-over-counterfeit-drugs [Accessed on November 10, 2014].
61. Joint Research Centre, Directorate-General for Research and Innovation. ( 2011) Monitoring Industrial Research: The 2011 EU Industrial R&D investment Scoreboard (2011) [online]. European Commission. Available at file:///C:/Users/Caitlin/Downloads/The%202011%20EU%20Industrial%20R&D%20Investment%20Scoreboard.pdf [Accessed on November 4, 2014].
62. Kahn U., Kreutzer S., Gill J. and Taylor D. ( 2012) ' Falsified Medicines and the Global Public's Health', Report of Matrix Insight and UCL School of Pharmacy. Available at http://www.ifpma.org/fileadmin/content/Publication/2012/UCL-Matrix_Insight-Falsified_Medicines_and_the_Global_Publics_Health.pdf [Accessed on November 10, 2014].
63. Kardas-Nelson M. ( 2013) Brazil's Sick CNY of Patent Exploitation [online]. Mail & Guardian. Available at http://mg.co.za/article/2013-10-11-00-brazils-sick-of-patent-exploitation [Accessed on November 6, 2014].
64. Kesselheim A. S. et al. ( 2011) ' "Pay for Delay" Settlements of Disputes over Pharmaceutical Patents', The New England Journal of Medicine, 365(15), 1533.
65. Kiddell-Monroe R., Iversen J. H. and Gopinathan U. ( 2013) Medical R&D Convention Derailed: Implications for the Global Health System [online]. Journal of Health Diplomacy. Available at http://www.ghd-net.org/sites/default/files/Medical%20R%20and%20D%20Convention%20Derailed%20-%20Implications%20For%20The%20Global%20Health%20System.pdf [Accessed on October 28, 2014].
66. Koethe J., Chi B., Megazzini K., Heimburger D. and Stringer J. ( 2009) ' Macronutrient Supplementation for Malnourished HIV-Infected Adults: A Review of the Evidence in Resource-Adequate and Resource-Constrained Settings', Clinical Infectious Diseases, 49(5), 787-98.
67. Lanjouw J. ( 2005) Patents, Price Controls and Access to New Drugs: How Policy Affects Global Market Entre. Working Paper No 11321, Centre for Global Development. Available at http://nber.org/papers/w11321 [Accessed on October 27, 2014].
68. Lanjouw J. and MacLeod M. ( 2005) ' Pharmaceutical R&D for Low-Income Countries: Global Trends and Participation by Indian Firms', Economic and Political Weekly, 40(39), 9-17.
69. Light D. W. ( 2005) ' Making Practical Markets for Vaccines', Public Library of Science Medicine, 2(10), Available at http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0020271#pmed-0020271-g001 [Accessed November 4, 2014].
70. Light D. W. ( 2009) Advanced Market Commitments: Current Realities and Alternate Approaches. Amsterdam: Health Action International Europe.
71. Light D. W. and Warburton R. ( 2011) Demythologizing the High Costs of Pharmaceutical Research. [online]. Biosocieties. Available at http://www.pharmamyths.net/files/Biosocieties_2011_Myths_of_High_Drug_Research_Costs.pdf [Accessed on November 4, 2014].
72. Light D. W. and Warburton R. ( 2012) Pharmaceutical R&D's Costly Myths. [online]. PLOS Blogs. Available at http://blogs.plos.org/speakingofmedicine/2012/03/07/pharmaceutical-rds-costly-myths/ [Accessed November 4, 2014].
73. Lipkus N. ( 2006) ' How to Understand Product Development: Public-Private Partnerships as Vehicles for Innovation in Combating Neglected Disease', Michigan State University Journal of Medicine & Law, 10, 385-427.
74. Manning J. M. ( 2011) ' The Herceptin Interception: New Zealand's Pharmac and the Herceptin Funding Issue', New Zealand Law Review, 4, 663-714.
75. Max Foundation. Gilvec International Patient Assistance Program [online]. Max Foundation. Available at http://themaxfoundation.org/gipap/default.aspx [Accessed on November 4, 2014].
76. MDG Gap Task Force ( 2008) 'Access to Affordable Essential Medicines', in Delivering on the Global Partnership for Achieving the Millennium Development Goals.' New York: United Nations Report.
77. Mehrotra S. and Jarrett S. ( 2002) ' Improving Basic Health Service Delivery in Low-Income Countries: "Voice" to the Poor', Social Science & Medicine, 54(11), 1685-90.
78. Merck. ( 2013) 25 Years: Merck Mectizan® Donation Program [online]. Merck. Available at http://www.merck.com/about/featured-stories/mectizan1.html [Accessed on November 4, 2014].
79. Merck. ( 2014) Merck Medical Outreach Program [online]. Merck. Available at http://www.merckresponsibility.com/access-to-health/merck-medical-outreach-program/ [Accessed on November 4, 2014].
80. MHRA. ( 2013) Winning the War Against Counterfeits [online]. MHRA. Available at http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Adviceandinformationforconsumers/counterfeitmedicinesanddevices/Casestudies/index.htm [Accessed on November 10, 2014].
81. Mok E. et al. ( 2010) ' Implementing Public Health Regulations in Developing Countries: Lessons from the OECD Countries', Journal of Law, Medicine and Ethics, 38(3), 508-19.
82. Moodie P., Metcalf S. and McNee W. ( 2003) ' Response from PHARMAC: Difficult Choices', The New Zealand Medical Journal, 116(1170), 1-6.
83. Molyneux D., Hotez P.J. and Fenwick A. ( 2005) ' "Rapid-Impact Interventions": How a Policy of Integrated Control for Africa's Neglected Tropical Diseases Could Benefit the Poor', PLoS Medicine, 2(11), 1064-70.
84. Muller-Langer F. ( 2011) Neglected Infectious Diseases: Are Push and Pull Mechanisms Suitable for Promoting Research? Max Planck Institute for Intellectual Property and Competition Law, Working Paper.
85. News Medical. ( 2011) What are Neglected Diseases? [online]. News Medical. Available at http://www.news-medical.net/health/what-are-neglected-diseases.aspx [Accessed October 27, 2014].
86. Newton P., McGready R., Fernandez F., Green M., Sunjio M., Bruneton C., Phanouvong S., Millet P., Whitty C., Talisuna A., Proux S., Christophel E., Malenga G., Singhasivanon S., Bojang K., Kaur H., Palmer K., Day N., Greenwood B., Nosten F. and White N. ( 2006a) ' Manslaughter by Fake Artesunate in Asia: Will Africa Be Next?', PLoS Medicine [online], 3(6), e197. Available at http://dx.doi.org/10.1371/journal.pmed.0030197 [Accessed on November 10, 2014].
87. Newton P., Green M., Fernández F., Day N. and White N. ( 2006b) ' Counterfeit Anti-Infective Drugs', The Lancet Infectious Diseases, 6(9), 602-13.
88. Niens Lauren M, Cameron A., Van de Poel E., Brouwer Werner B. F. and Laing R. ( 2010) ' Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing World', PLoS Medicine, 7(8), e1000333. doi: 10.1371/journal.pmed.1000333
89. Oke E. K. ( 2013) ' Using the Right to Health to Enforce the Corporate Responsibilities of Pharmaceutical Companies with Regard to Access to Medicines', Journal of Health Diplomacy, 1(1), 1-15.
90. Orach C. ( 2009) ' Health Equality: Challenges in Low Income Countries', African Health Sciences, 9(Suppl 2), S49-S51.
91. Organization for Economic Co-operation and Development (OECD). ( 2005) Drug Spending in OECD Countries Up by Nearly a Third Since 1998, According to New OECD Data [online]. Organization for Economic Co-operation and Development. Available at http://www.oecd.org/general/drugspendinginoecdcountriesupbynearlyathirdsince1998accordingtonewoecddata.htm [Accessed October 27, 2014].
92. Park C., Prabhala A. and Berger J. ( 2013) ' Using Law to Increase Treatment Access in South Africa: An Analysis of Patent, Competition and Medicines Law', United Nations Development Programme. Available at http://www.undp.org/content/dam/undp/library/hivaids/English/using_law_to_accelerate_treatment_access_in_south_africa_undp_2013.pdf [Accessed on November 6, 2014].
93. Pereira C., Cumbi A., Malalane R., Vaz F., McCord C., Bacci A. and Bergstrom S. ( 2007) ' Meeting the Need for Emergency Obstetric Care in Mozambique: Work Performance and Histories of Medical Doctors and Assistant Medical Officers Trained for Surgery', British Journal of Obstetrics and Gynaecology, 114(12), 1530-33.
94. Pharmaceutical Security Institute. ( 2014a) Safe Medicines [online]. Pharmaceutical Security Institute. Available at http://www.psi-inc.org/safeMedicines.cfm [Accessed on November 10, 2014].
95. Pharmaceutical Security Institute. ( 2014b) About Us [online]. Pharmaceutical Security Institute. Available at http://www.psi-inc.org/index.cfm [Accessed on November 10, 2014].
96. Plahte J. ( 2012) ' Is the Pneumococcal Vaccine Advance Market Commitment Motivating Innovation and Increasing Manufacturing Capacity? Some Preliminary Answers', Vaccine 30(14), 2462-66.
97. PRWeb. ( 2013) Layoffs in Pharmaceutical Industry due to Productivity Crisis in R&D; CBCD Offers a New Technology. [online]. PRWeb. Available at http://www.prweb.com/releases/2013/10/prweb11222203.htm [Accessed on November 4, 2014].
98. Pugatch M. ( 2011) ' Patent Pools and Collaborative Initiatives: Assessing the Efficacy of Alternatives to IP in the Development of New Pharmaceutical Drugs, Especially for Neglected Diseases - An Empirical Analysis', European Journal of Risk Regulation, 4, 566-71.
99. Pugatch M., Chu R. and Torstensson D. ( 2012) Assembling the Pharmaceutical R&D Puzzle for Needs in the Developing World. Commissioned by International Federation of Pharmaceutical Manufacturers and Associations. Available at http://www.ifpma.org/fileadmin/content/Publication/2012/Assembling_the_RD_puzzle_FINAL.pdf [Accessed October 27, 2014].
100. Ridley D., Grabowski H. and Moe J. ( 2006) ' Developing Drugs for Developing Countries', Health Affairs, 25(2), 313-24.
101. Robertson A., Stefanakis R., Joseph D. and Moree M. ( 2012) ' The Impact of the US Priority Review Voucher on Private-Sector Investment in Global Health Research and Development', PLoS Neglected Tropical Diseases, 6(8), e1750. Available at doi: 10.1371/journal.pntd.0001750 Accessed on November 4, 2014].
102. Saez C. ( 2013) New EU Customs Regulation Might Allow Wrongful Seizures of Generic Drugs in Transit, NGOs Say. [online]. Intellectual Property Watch. Available at http://www.ip-watch.org/2013/10/17/new-eu-custom-regulation-might-allow-wrongful-seizures-of-generic-drugs-in-transit-ngos-say/?utm_source=post&utm_medium=email&utm_campaign=alerts [Accessed on November 10, 2014].
103. Sakhia S. ( 2013) Paladin Receives Priority Review Status from FDA for Impavido® NDA Submission. [online]. Paladin Labs, Inc. Available at http://online.wsj.com/article/PR-CO-20130619-909846.html [Accessed on November 4, 2014].
104. Scannell J. W., Blanckley A., Boldon H. and Warrington B. ( 2012) ' Diagnosing the Decline in Pharmaceutical R&D Efficiency', Nature Reviews Drug Discovery, 11(3), 191-200.
105. Serafino D. ( 2007) Survey CNY of Patent Pools Demonstrates Variety of Purposes and Management Structures. [online]. Knowledge Ecology International Research Note 6. Available at http://keionline.org/content/view/69/1 [Accessed on November 4, 2014].
106. Scudellari M. ( 2011) ' Are Advance Market Commitments for Drugs a Real Advance?', Nature Medicine, 17(2), 139.
107. Shakoor O., Taylor R. B. and Behrens R. H. ( 1997) ' Assessment of the Incidence of Substandard Drugs in Developing Countries', Tropical Medicine & International Health, 2(9), 839-45.
108. Simoens S. ( 2012) ' What Is the Value for Money of Medicines? A Registry Study', Journal of Clinical Pharmacy and Therapeutics, 37(2), 182-86.
109. Smith L. and Yadav P. ( 2011) 'Improving Access to Medicines for Non-Communicable Diseases through Better Supply Chains', In: Galambos L and Sturchio J (eds), Addressing the Gaps in Global Policy and Research for Non-Communicable Diseases, P 9-L 12. Available at IR http://www.ifpma.org/fileadmin/content/Publication/2013/Johns_Hopkins_Addressing_the_Gaps_in_Global_Policy_and_Research_for_NCDs.pdf [Accessed on November 10, 2014].
110. Stefanakis R., Robertson A.S., Ponder E.L. and Moree M. ( 2012) ' Analysis of Neglected Tropical Disease Drug and Vaccine Development Pipelines to Predict Issuance of FDA Priority Review Vouchers over the Next Decade', PLoS Neglected Tropical Diseases, 6(10), e1803. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493373/pdf/pntd.0001803.pdf [Accessed November 4, 2014].
111. Sutar M., Gawhane D. and Tenpe C.R. ( 2013) ' Study of Drug Regulatory Approval Process an Comparative Requirement of Common Technical Documents (CTD) in Europe, USA and India in Coordination with Drug Developmental Process', International Journal of Pharmaceutical Sciences Review and Research, 20(2), 68-79.
112. Sutton M. ( 2013) Pay for Delay: The US Supreme Court Rules on CNY Reverse Patent Settlements. [online]. Mondaq. Available at http://www.mondaq.com/australia/x/248706/Patent/Pay+for+delay+The+US+Supreme+Court+rules+on+reverse+patent+settlements [Accessed on November 6, 2014].
113. The Partnership for Safe Medicine ( 2011) Counterfeit Drug Incident Encyclopedia. [online]. The Partnership for Safe Medicines. Available at http://www.safemedicines.org/nigeriabound-hivaids-drugs-seized-in-netherlands.html [Accessed on November 10, 2014].
114. The Partnership for Safe Medicines ( 2014) Working Together to Protect the Safety of Your Prescription Drugs. [online]. Available at http://www.safemedicines.org/ Accessed on November 10, 2014].
115. The US President's Emergency Plan for AIDS Relief (PEPFAR). About PEPFAR [online]. Office of US Global AIDS Coordinator and the Bureau of Public Affairs, US State Department. Available at http://www.pepfar.gov/about/index.htm [Accessed on November 10, 2014].
116. The US President's Emergency Plan for AIDS Relief (PEPFAR). Latest Results [online]. Office of US Global AIDS Coordinator and the Bureau of Public Affairs, US State Department. Available at http://www.pepfar.gov/funding/results/index.htm [Accessed on November 10, 2014].
117. Thomas B. and Gostin L. ( 2013) ' Tackling the Global NCD Crisis: Innovations in Law and Governance', The Journal of Law, Medicine and Ethics, 41, 16-27.
118. Treatment Action Campaign ( 2013) DTI's Draft IP Policy Lays Foundation to Prevent Abusive Patenting. [online]. Fix CNY the Patent Laws. Available at http://www.fixthepatentlaws.org/?p=657.
119. United Nations Office on Drugs and Crime ( 2009) Transnational Trafficking and the Rule of Law in West Africa: A Threat Assessment. Available at http://www.unodc.org/documents/data-and-analysis/Studies/West_Africa_Report_2009.pdf [Accessed on November 10, 2014].
120. Vacca R. ( 2013) Intellectual Property and Public Health - A White Paper. Akron Research Paper No. 13-11, School of Law, University of Akron.
121. ViiV Healthcare. Community Partnerships [online]. ViiV Healthcare. Available at http://www.viivhealthcare.com/community-partnerships.aspx [Accessed on November 10, 2014].
122. ViiV Healthcare. ( 2011) ViiV Healthcare's Positive Action and the International HIV/AIDS Alliance Tackle HIV Stigma in Six Central American Countries [online]. ViiV Healtcare. Available at http://www.viivhealthcare.com/media/press-releases/2011/february/viiv-healthcare%E2%80%99s-positive-action-and-the-international-hivaids-alliance-tackle-hiv-stigma-in-six-central-american-countries.aspx [Accessed on November 10, 2014].
123. Yadav P. ( 2010) ' Differential Pricing for Pharmaceuticals: Review of Current Knowledge, New Findings and Ideas for Action', Study Conducted for the UK Department for International Development (DFID). Available at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/67672/diff-pcing-pharma.pdf [Accessed on November 4, 2014].
124. Watal J. ( 2000) ' Pharmaceutical Patents, Prices and Welfare Losses: Policy Options for India under the WTO TRIPS Agreement', World Economics, 23(5), 733-52.
125. White-Guay B. ( 2011) 'Regulation of Medicines in Low and Middle-Income Countries: Current Challenges and Future Prospects', In: Galambos L and Sturchio J (eds), Addressing the Gaps in Global Policy and Research for Non-Communicable Diseases. Report of the IFPMA Non-Communicable Diseases Working Group pp. 4-8.
126. World Bank ( 2013) Health Expenditure Per Capita. [online]. World Bank. Available at http://data.worldbank.org/indicator/SH.XPD.PCAP [Accessed October 27, 2014].
127. World Bank How Does the World Bank Classify Countries. [online]. World Bank. Available at http://datahelpdesk.worldbank.org/knowledgebase/articles/378834-how-does-the-world-bank-classify-countries [Accessed on October 27, 2014].
128. World Health Organization (WHO) ( 2001) Report of the Workshop on Differential Pricing & Financing of Essential Drugs. Available at http://apps.who.int/medicinedocs/en/d/Jh2951e/1.html [Accessed November 4, 2014].
129. World Health Organization (WHO) ( 2003) The 17 Neglected Tropical Diseases. [online]. World Health Organization. Available at http://www.who.int/neglected_diseases/diseases/en [Accessed October 27, 2014].
130. World Health Organization (WHO) ( 2004) The World Medicines Situation. Available at http://apps.who.int/medicinedocs/pdf/s6160e/s6160e.pdf [Accessed October 27, 2014].
131. World Health Organization (WHO) ( 2008) Task Shifting: Rational Redistribution of Tasks Among Health Workforce Teams. Geneva: World Health Organization.
132. World Health Organization (WHO) ( 2009) Counterfeits FAQ. [online]. World Health Organization. Available at http://www.who.int/medicines/services/counterfeit/faqs/QACounterfeit-October2009.pdf [Accessed on November 10, 2014].
133. World Health Organization (WHO) ( 2010) Working to Overcome the Global Income of Neglected Tropical Diseases. Available at http://whqlibdoc.who.int/publications/2010/9789241564090_eng.pdf [Accessed on October 28, 2014].
134. World Health Organization (WHO) ( 2012) Spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines (fact sheet). [online]. World Health Organization. Available at http://www.who.int/mediacentre/factsheets/fs275/en/ [Accessed on November 10, 2014].
135. World Health Organization (WHO) ( 2013) Neglected Tropical Diseases. [online]. World Health Organization. Available at http://www.who.int/neglected_diseases/en/ [Accessed on October 27, 2014].
136. World Health Organization (WHO) . ( 2013) 'Report of the Steering Committee of the Member State Mechanisms on Substandard/Spurious/Falsely-Labelled/Falsified/Counterfeit Medical Products, including the Draft Workplan as Proposed by the Steering Committee'. Report A/MSM/2/2. Available at http://apps.who.int/gb/ssffc/pdf_files/A_MSM2_2-en.pdf [Accessed on November 10, 2014].
137. World Health Organization (WHO) Commission on Macroeconomics and Health ( 2001) Macroeconomics and Health: Investing in Health for Economic Development. World Health Organization. Available at http://whqlibdoc.who.int/publications/2001/924154550x.pdf [Accessed on October 27, 2014].
138. World Health Organization (WHO) Consultative Expert Working Group on Research and Development: Financing and Coordination ( 2012) Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination. World Health Organization. Available at http://www.who.int/phi/CEWG_Report_5_April_2012.pdf?ua=1 [Accessed on October 28, 2014].
139. World Health Organization (WHO), World Intellectual Property Organization (WIPO) and World Trade Organization (WTO) ( 2012) Promoting Access to Medical Technologies and Innovation: Intersections between public health, intellectual property and trade. Available at http://www.wto.org/english/res_e/booksp_e/pamtiwhowipowtoweb13_e.pdf [Accessed on November 11, 2014].
140. World Intellectual Property Organization (WIPO) Guiding Principles of WIPO Re:search. [online]. World Intellectual Property Organization. Available at http://www.wipo.int/research/en/about/guiding_principles.html [Accessed on November 4, 2014].
141. World Intellectual Property Organization (WIPO) ( 2013) R&D, Innovation and Patents. [online]. Available at http://www.wipo.int/patent-law/en/developments/research.html [Accessed on November 4, 2014].